Corbevax Vaccine Gets Emergency Use Approval For Children

The vaccine has been approved for use in children aged 12-18 years. Read more about the vaccine here.

After Bharat Biotech's Covaxin, Biological E Limited's Corbevax has now received emergency use authorization (EUA) for treating children, from the Drugs Controller General of India (DCGI).

The Corbevax vaccine received approval from the DCGI late Monday, 21 February, for use in children and adolescents aged 12 to 18 years.

India had been administering Bharat Biotech's Covaxin for use in adolescents between 15 and 18 years, 3 since January 2022.

The DCGI cleared Corbevax for restricted use on adults in December 2021, alongside Serum Institute of India's Covovax and Merck's antiviral COVID pill, Molnupiravir.